Mr. Wong Sai Hung (“Mr. Wong”), aged 61, is an executive Director and the Vice-Chairman of the Board (“Vice-Chairman”). He is also a member of nomination committee and remuneration committee. Mr. Wong joined the Group in June 2008 as non-executive Director. He had been re-designated as executive Director between August 2012 to April 2013 and in January 2016, as the Vice Chairman between July 2009 to August 2012, May 2013 to July 2014 and in October 2016. He also holds directorships in certain subsidiaries of the Company. Mr. Wong graduated from Hong Kong Polytechnic University with a Higher Diploma in Business Studies (Marketing). Currently, he is an independent non-executive director of Ping An Insurance (Group) Company of China, Ltd. (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2318) and JP Morgan Chinese Investment Trust plc (an investment trust listed on the London Stock Exchange); a non-executive director of Credit China Holdings Limited (the shares of which are listed on the Growth Enterprise Market of the Stock Exchange, stock code: 8207) and a director of One Asset Management Limited (a company incorporated in Thailand). Previously, Mr. Wong was an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 388); an executive director of LW Asset Management Advisors Limited; a non-executive director of ARN Investment SICAV (an investment company listed on the Luxembourg Stock Exchange) and ARN Asian Enterprise Fund Limited (formerly listed on the Irish Stock Exchange); the chief executive officer and an executive director of ICBC (Asia) Investment Management Company Limited; the chief executive director of BOCI Prudential Asset Management Limited and a regional managing director of Prudential Portfolio Managers Asia.
Dr. Shao Zhengkang (“Dr. Shao”), aged 64, is an executive Director. He is also a member of nomination committee and remuneration committee. Dr. Shao joined the Group in May 2013 as the general manager and had been appointed as Chief Executive Officer in September 2013. He also holds directorships in certain subsidiaries of the Company. Dr. Shao has 13 years’ experience in bio-medical industry. Prior to joining the Company, he had been the director and the general manager of a biomedical technology company in the PRC. From 1999 to 2002, he was an executive director and the general manager of China Everbright Limited, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 165). During the period, Dr. Shao also served as non-executive director of several companies listed on the Main Board of the Stock Exchange. Before joining the Everbright Group, he was a deputy chief of the International Department of the People’s Bank of China’s Head Office, and as an economist of the Asia office of International Monetary Fund. Dr. Shao holds a Bachelor’s degree in Arts from Shanghai Institute of Foreign Languages, China. He has also obtained a Master’s degree in Business Administration from the George Washington University, U.S.A. and a Doctorate’s degree from the International Management Centre, U.K.. Dr. Shao possesses over 30 years’ experience in banking, corporate finance, treasury business development and corporate management.
Mr. Chen Chunguo (“Mr. Chen”), aged 44, is an executive Director and chief executive officer ("CEO"). He is also a member of nomination committee and remuneration committee. Mr. Chen joined the Company in October 2016 as president and re-designated as CEO in February 2017. He graduated from Dongbei University of Finance and Economics and obtained a Master’s degree. From 1996 to 2012, Mr. Chen served as President of 大連實德集團 (Dalian Shide Group Co., Ltd.*) who was responsible for the overall management of this 3000-employee group. Under his management, he established 8 production bases across the country for new construction materials, all of which were put into operation successfully, and developed over 100 distribution channels, making “Shide Profiles” one of the well-known brands in the People’s Republic of China (the “PRC”). During his appointment, he led the investment in and acquisition of 河北凌雲股份有限公司 (Lingyun Industrial Corporation Limited*(SSE code: 600480)) and 寧夏大元股份有限公司 (Ningxia Dayuan Chemical Co., Ltd.*(SSE code: 600146)), and invested in a number of financial institutions such as 大連銀行股份有限公司 (Bank of Dailian Co., Ltd.), 太平洋保險股份有限公司 (China Pacific Insurance Co., Ltd.*), 生命人壽保險股份有限公司 (Sino Life Insurance Co., Ltd.*), 華匯人壽保險股份有限公司（Sino-Conflux Insurance Company Ltd.*）, 鐵嶺銀行股份有限 公司（Bank of Tieling Co., Ltd.*) and 景順長城基金管理有限公司 (Invesco Great Wall Fund Management Company Limited*）, etc. Meanwhile, during this period, he also formed 大連實德石化有限公司 (Dalian Shide Petrochemical Co., Ltd.*), 實德集團控股有限公司（港資）（Shide Group (Hongkong) Holdings Co., Ltd.*), 大連實德足球俱樂部 (Dalian Shide Football Club*), 大連實德投資有限公司 (Dalian Shide Investment Co., Ltd.*) and other dozens of companies. In total, Mr. Chen managed nearly a hundred of parents and subsidiaries and a billion-dollar group during his service in Dalian Shide Group Co., Ltd. From 2012 to 2016, as President of 大連海潤來集團 (Hairunlai Group Co., Ltd.*), Mr. Chen has led the investment in and acquisition of 盛銀互聯網金融株式會社 (Shengyin Internet Financial Services Co., Ltd.*, based in Korea) and the investment in 百斯頓食品有限公司 (Beston Global Food Company Ltd.*, based in Australia), 河北唐宋互聯網大數據有限公司 (Chinatsi Big Data Inc.*) and 國金金融租賃有限公司 (Guojin Financial Leasing Co., Ltd.*), etc. In addition, Mr. Chen has integrated the group’s resources and implemented an overall transition in the group. Mr. Chen is also the chairman of 上海湧涵股權投資有限公司 (Shanghai Yonghan Equity Investment Co., Ltd.*). Mr. Chen has 20 years of relevant experience and has accumulated abundant experience in investment and M&A as well as corporation management.
* for identification purposes only
Prof. Cui Zhanfeng (“Prof. Cui”), aged 54, is a non-executive Director and the Chairman of the Board (“Chairman”). He is also a member of audit committee. Prof. Cui joined the Group in November 2013 as consultant. He also holds directorship in one of the subsidiaries of the Company. Prof. Cui obtained his Bachelor’s degree of Science from Inner Mongolia Polytechnic University, the People’s Republic of China (the “PRC”) in 1982, and a master’s degree of Science in 1984 and doctor’s degree of Philosophy in 1987 from Dalian University of Technology, the PRC. Prof. Cui was a postdoctoral Fellow in the Bioengineering Unit, Strathclyde University, the United Kingdom from 1988 to 1991 and a Lecturer in Edinburgh University from 1991 to 1994. He moved to the Oxford University as a University Lecturer from 1994 to 1999 and was promoted to a Reader in 1999. In 2000, he was elected to the Donald Pollock Chair of Chemical Engineering in the Oxford University at the age of 37. He is also a Professorial Fellow of Hertford College, the Oxford University. He was a visiting professor to Georgia Institute of Technology, the United States of America (“USA”) in 1999 and University of Minnesota, USA in 2004, and to several universities in China. He is a Chartered Scientist, a Chartered Engineer, and a Fellow of the Institution of Chemical Engineers. Prof. Cui was awarded the Doctor of Science (DSc) by the Oxford University in 2009. In 2013, Prof. Cui was elected to a Fellow of the Royal Academy of Engineering (FREng).
Prof. Cui was the first Chinese who was elected to a Statutory Chair in the Oxford University. He has a wide range of collaborative activities in the PRC with Chinese Universities and Chinese Academy of Sciences. He was a Chang Jiang Scholar of the Ministry of Education of the PRC and has acted as an adviser to several governmental organisations, including the Overseas Chinese Affair Office of the State Council.
Dr. Ray Yip (“Dr. Yip”), aged 66, is a non-executive Director. He is also a member of the audit committee, nomination committee and remuneration committee of the Company. Dr. Yip joined the Group in February 2017. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in China in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation (the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the People’s Republic of China (“China”).
Dr. Yip’s major contributions to the global health include: refining the international criteria for screening for malnutrition and anemia and increasing the awareness of diarrhea as a major contributor to acute malnutrition. His work in China has resulted in the mainstreaming of hepatitis B vaccine for routine immunization, the adoption of hospital-based delivery as a strategy which significantly reduced maternal mortality, transformation of the national AIDS response to one targeting those high-risk groups by accepting the role of civil society and assisting in engineering the policy support for tobacco control at the top level.
Dr. Yip established the Foundation’s mission in China by assisting the government in addressing the key public health issues such as HIV and tobacco. He also transformed the Foundation’s strategy in giving it a new focus “China-for-Africa” which includes identifying successful Chinese experience and technology to assist in the development of Africa. Since 2017, Dr. Yip has served as a special advisor focusing on health and clean energy for bgC3, a think-tank headed by Bill Gates.
Dr. Yip served at the faculty of the University of California-San Francisco between 1990 and 1994 and was an adjunct professor at the Friedman School and Nutrition Science and Policy of Tufts University between 2006 and 2010. Currently, Dr. Yip is an adjunct professor at the Research Centre for Public Health of Tsinghua University.
Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric haematologist-oncologist.
Professor Xiong Chengyu (“Prof. Xiong”), aged 62, is a non-executive Director. He is also a member of the audit committee of the Company. Prof. Xiong joined the Group in March 2017. Prof. Xiong is currently a professor and a doctoral supervisor of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong has extensive experience in new media studies, media development and journalism. He was a member of each of the Advisory Committee for State Informatisation* (國家信息化專家諮詢委員會委員) and the Advisory Committee for Internet Development and Management* (國家互聯網發展與管理專家諮詢委員會委員), and served as a vice dean of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong currently serves as a member of the University Academic Committee and the chairman of the National Research Center of Cultural Industries in Tsinghua University in China. Professor Xiong was an independent director of each of Hunan TV & Broadcast Intermediary Co., Ltd.* (湖南電廣傳媒股份有限公司) (Shenzhen Stock Exchange: 000917) and China South Publishing & Media Group Co., Ltd.* (中南出版傳媒集團股份有限公司) (Shanghai Stock Exchange: 601098). He currently serves as an independent director of Jiangsu Broadcasting Cable Information Network Corporation Limited* (江蘇省廣電有綫信息網絡股份有限公司) (Shanghai Stock Exchange: 600959).
* For identification purposes only
Mr. Lui Tin Nang (“Mr. Lui”), aged 59, is an independent non-executive Director. He is also the chairman of audit committee and nomination committee, and a member of remuneration committee of the Company. Mr. Lui joined the Group in September 2004. He obtained a Bachelor Degree in Science from the University of Leeds and a Master degree in Business Administration from the University of Bradford in United Kingdom, and a Postgraduate Diploma in insolvency from Hong Kong Institute of Certified Public Accountants (“HKICPA”). Mr. Lui is a fellow member of the HKICPA (Practising), the Institute of Chartered Accountants in England & Wales, the Taxation Institute of Hong Kong and The Society of Chinese Accountants and Auditors. He is also a member of the Chartered Institute of Management Accountant, Institute of Certified Public Accountants in Australia and the Certified Tax Adviser. Mr. Lui has years of experience in accounting, auditing, taxation, corporate finance and business advisory. He was an independent non-executive director of Vital Pharmaceutical Holdings Limited, now known as CGN Mining Company Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1164) and National Investments Fund Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1227). Mr. Lui is currently an independent non-executive director of Brilliant Circle Holdings International Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1008) and Noble House (China) Holdings Limited, now known as Northern New Energy Holdings Limited (the shares of which are listed on the GEM of the Stock Exchange, stock code: 8246).
Mr. Pang Chung Fai Benny (“Mr. Pang”), aged 44, is an independent non-executive Director. He is also the chairman of remuneration committee (appointed on 23 March 2015), a member of the audit committee and nomination committee of the Company. Mr. Pang joined the Group in September 2012. He is the managing partner of Loeb & Loeb LLP (Hong Kong). Between 1997 and 2009, Mr. Pang practiced as a lawyer with several international law firms in Hong Kong and Sydney. He received his Bachelor degree in Laws with honours from Bond University, Australia, in 1996. In 1997, Mr. Pang obtained his Graduate Diploma in Legal Practice and Master Degree in Laws from The College of Law, Sydney and the University of New South Wales, Australia, respectively. He has been admitted as a legal practitioner of the Supreme Court of New South Wales, Australia since 1997 and as a solicitor of the High Court of Hong Kong since 2009. Mr. Pang is a member of both the Law Society of New South Wales, Australia and the Law Society of Hong Kong. He is currently an independent non-executive director of Yuanda China Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2789), and Goldenmars Technology Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 3638).
Mr. Chan Bing Woon, SBS, JP, (“Mr. Chan”), aged 71, is an independent non-executive Director. He is also a member of the audit committee, nomination committee and remuneration committee of the Company. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has about 40 years’ experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong, and the chairman of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital. Mr. Chan was a member of the Hospital Authority and a past chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).
Mr. Wang Hui (“Mr. Wang”), aged 58, is an independent non- executive Director. He is also a member of the audit committee, nomination committee and remuneration committee of the Company. Mr. Wang joined the Group in June 2015. Mr. Wang is currently the CEO of First China Capital, Inc. (“FCC”), the Committee Member of China Society of Economic Reform and the Governor of Pardee RAND Graduate School of US RAND Corporation (“RAND”). Mr. Wang acquires financial and economic knowledge, and has extensive experience in mergers and acquisitions. Led by Mr. Wang, FCC provides financial advisory services in mergers and acquisitions, strategic alliance specifically for Chinese and foreign corporates. Over the past two decades, FCC served as the financial advisor to Morgan Stanley, UBS, Sumitomo Mitsui Banking Corporation, China’s banks and other financial and business institutions, and some of the successful transactions, such as UBS acquiring Beijing Securities, are considered as landmarks in the industry. From 1988 to 1993, Mr. Wang conducted research at RAND (a non-profit international research institution), and then became the adjunct researcher of RAND for a long time. From 1986 to 1988, Mr. Wang was the Assistant to President of China Institute of Economic Reform, during the period he completed a research report concerning new economic order with contract as core and it led to a national reform policy. Mr. Wang has published more than 20 academic works over the years. Mr. Wang holds a Master of Economics from China Academy of Social Sciences and a Ph.D. in Policy Analysis from Pardee RAND Graduate School.
Mr. Wong Yiu Kit Ernest (“Mr. Wong”), aged 49, is an independent non-executive Director. He is also the member of audit committee, nomination committee and remuneration committee of the Company. Mr. Wong joined the Group in February 2017. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited, the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (HKEx stock code: 8077) since October 2014. Mr. Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code: 1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016.
Mr. Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.
Mr. Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.
Mr. Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.